arrow
E

Eric V. Li

Mayo Clinic
H指数:14
被引数:1,542

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of Patients With Favorable Intermediate Risk Gleason Grade Group 2 Prostate Cancer Undergoing Radical Prostatectomy in the MRI Era: Refining Active Surveillance Selection Criteria

MRI时代下 Gleason 等级组2的预后良好中等风险前列腺癌患者行根治性前列腺切除术的结局:优化主动监测选择标准

2026-06-080
PRE
RESPONSE OF VENOUS TUMOR THROMBI IN RENAL CELL CARCINOMA TO IMMUNE CHECKPOINT INHIBITOR THERAPY: A MULTICENTER RETROSPECTIVE COHORT STUDY

肾细胞癌静脉肿瘤血栓对免疫检查点抑制剂治疗的反应:一项多中心回顾性队列研究

2026-05-010
PRE
NCCN RISK GROUPS DO NOT PREDICT ADVERSE PATHOLOGY OR ONCOLOGIC OUTCOMES AMONG PATIENTS WITH GRADE GROUP 1 PROSTATE CANCER UNDERGOING RADICAL PROSTATECTOMY IN THE CONTEMPORARY MRI ERA

NCCN风险组不能预测MRI时代行根治性前列腺切除术的Gleason评分分组1级前列腺癌患者的病理不良结果或肿瘤学结局

2026-05-010
PRE
Atrial fibrillation-induced neurocognitive and vascular dysfunction is averted by mitochondrial oxidative stress reduction

心房颤动诱导的神经认知和血管功能障碍可通过减少线粒体氧化应激来避免。

2025-11-240
OA
AI-driven screening of equivocal prostate IHC cases: development and validation of a screening and cancer detection framework

AI驱动的模糊前列腺IHC病例筛查:筛查和癌症检测框架的开发与验证

2025-10-010
OAAI
Prevalence of Potential Candidates for Targeted Therapies According to Treatment-related Transcriptomic Signatures Among 140 548 Patients with Nonmetastatic Prostate Cancer

根据治疗相关转录组特征,在140 548例非转移性前列腺癌患者中靶向治疗潜在候选者的患病率

2025-05-100
PRE
Utility of 18F-DCFPyL PET for local staging for high or very high risk prostate cancer for patients undergoing radical prostatectomy

18F-DCFPyL PET在前列腺癌根治术患者高危或极高危前列腺癌局部分期中的应用

2025-02-101
PRE
Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naive Prostate Cancer

前列腺特异性膜抗原在治疗 naive 前列腺癌中的分子特征

2024-12-011
PRE